Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | RXRB | P28702 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL28598974 | 0.96 | ALOX15 (0.57) | ALOX15SMN1; SMN2ALDH1A1TSHRRXRA | |
| SCHEMBL7813264 | 0.94 | ALOX15 (0.55) | ALOX15SMN1; SMN2ALDH1A1TSHRRXRA | |
| SCHEMBL23512464 | 0.94 | ALOX15 (0.55) | ALOX15SMN1; SMN2ALDH1A1TSHRRXRA | |
| SCHEMBL339492 | 0.85 | ALOX15 (0.81) | ALOX15SMN1; SMN2ALDH1A1TSHRFFAR1 | |
| SCHEMBL12612087 | 0.85 | LMNA (0.60) | ALOX15SMN1; SMN2ALDH1A1TSHRFFAR1 | |
| SCHEMBL11530406 | 0.84 | RAB9A (0.56) | SMN1; SMN2ALDH1A1RXRARXRBKDM4E | |
| SCHEMBL4651646 | 0.83 | L3MBTL1 (0.67) | ALOX15SMN1; SMN2ALDH1A1TSHRFFAR1 | |
| SCHEMBL13967467 | 0.83 | EPHX2 (0.76) | SMN1; SMN2RAB9AKMT2ANPC1MEN1 | |
| Ammonia Solution, Strong SCHEMBL9651953 | 0.83 | LMNA (0.58) | ALOX15SMN1; SMN2ALDH1A1TSHRFFAR1 | |
| SCHEMBL1480561 | 0.82 | RXRA (0.53) | SMN1; SMN2ALDH1A1RXRARXRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070110844-A1 | REDUCED SWEETNESS CONFECTIONARY COMPOSITIONS AND COATED/FILLED FOOD PRODUCTS | GENERAL MILLS, INC. | 2007-05-17 | — | — | US | claimed |
| EP-0159864-B1 | METHOD OF MODIFYING TASTE | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1989-07-19 | — | — | EP | claimed |
| EP-0159864-A2 | Method of modifying taste | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1985-10-30 | — | — | EP | claimed |
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-05-19 | — | — | US | disclosed |
| US-20260091009-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE | Lu, Qun (US) | 2026-04-02 | — | — | US | disclosed |
| US-12285393-B2 | Roles of modulators of intersectin-Cdc42 signaling in Alzheimer's disease | Lu, Qun (US) | 2025-04-29 | — | — | US | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3470407-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230165815-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER?S DISEASE | Lu, Qun (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2002056885-A1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6350756-B1 | USEFUL FOR TREATING CANCER; (20S) ESTERS WITH AN OXYALKANOIC ACID; | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-02-26 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5413892-A | A phenoxyacetic acid charge control agent | HODOGAYA CHEMICAL CO., LTD. (JP) | 1995-05-09 | — | — | US | disclosed |
| US-5045336-A | Reducing sweet taste of high sugar foods, organic acids and acid salts | AMSTAR SUGAR CORPORATION (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0159864-B1 | METHOD OF MODIFYING TASTE | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1989-07-19 | — | — | EP | disclosed |
| EP-0159864-A2 | Method of modifying taste | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1985-10-30 | — | — | EP | disclosed |
| US-4013451-A | 2-(SUBSTITUTED PHENOXY)PROPIONIC ACID | PHILAGRO S.A. (FR) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12285393-B2 | Roles of modulators of intersectin-Cdc42 signaling in Alzheimer's disease | CDC42, MDN1, HASPIN | ALOX15 4617/4885SMN1; SMN2 1859/4885ALDH1A1 4366/4885 |
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | MDH2, MDH1, ME2 | ALOX15 2912/4885SMN1; SMN2 2420/4885ALDH1A1 192/4885 |
| US-20260091009-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE | CDC42, GAP43, HASPIN | ALOX15 4278/4885SMN1; SMN2 1681/4885ALDH1A1 4661/4885 |
| US-20230165815-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER?S DISEASE | CDC42, MDN1, GAP43 | ALOX15 4629/4885SMN1; SMN2 1895/4885ALDH1A1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.